Smith, A H
Jensen, K P
Li, J
Nunez, Y
Farrer, L A
Hakonarson, H
Cook-Sather, S D
Kranzler, H R
Gelernter, J
Article History
Received: 1 October 2016
Revised: 8 December 2016
Accepted: 13 December 2016
First Online: 24 January 2017
Competing interests
: Dr Kranzler reports being a consultant, continuing medical education (CME) speaker or advisory board member for Alkermes, Indivior, Lundbeck and Otsuka and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the past 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer and XenoPort. The other authors declare no conflict of interest.